Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has issued an announcement.
Tonix Pharma disclosed that the information related to its financial results or operations referenced in a specific filing section is being incorporated by reference into the current disclosure, without providing additional operational, strategic, or performance details in this release.
The most recent analyst rating on (TNXP) stock is a Sell with a $16.50 price target. To see the full list of analyst forecasts on Tonix Pharma stock, see the TNXP Stock Forecast page.
Spark’s Take on TNXP Stock
According to Spark, TipRanks’ AI Analyst, TNXP is a Neutral.
The score is held down primarily by weak financial performance (losses and cash burn) and bearish technicals (below major moving averages with negative MACD). Positive corporate developments (commercial launch and regulatory/pipeline progress) provide support but do not fully offset the current profitability and trend risks; valuation is difficult to assess due to negative earnings.
To see Spark’s full report on TNXP stock, click here.
More about Tonix Pharma
Average Trading Volume: 596,109
Technical Sentiment Signal: Sell
Current Market Cap: $220.5M
For a thorough assessment of TNXP stock, go to TipRanks’ Stock Analysis page.